• SPX
  • 6090.27
  • 0.25 %
  • 15.1602
  • DJI
  • 44642.52
  • -0.28 %
  • -123.1914
  • N225
  • 39160.28
  • 0.18 %
  • 69.33
  • FTSE
  • 8308.61
  • -0.49 %
  • -40.7695
  • IXIC
  • 19859.773
  • 0.81 %
  • 159.0508
SELLAS Life Sciences Group, Inc. (SLS) Stock Price, News & Analysis

SELLAS Life Sciences Group, Inc. (SLS) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.15

$0.05

(4.11%)

Day's range
$1.08
Day's range
$1.19
50-day range
$1.05
Day's range
$1.39
  • Country: US
  • ISIN: US81642T2096
52 wk range
$0.5
Day's range
$1.72
  • CEO: Dr. Angelos M. Stergiou M.D., ScD h.c.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -11.69
  • Piotroski Score 2.00
  • Grade Overweight
  • Symbol (SLS)
  • Company SELLAS Life Sciences Group, Inc.
  • Price $1.15
  • Changes Percentage (4.11%)
  • Change $0.05
  • Day Low $1.08
  • Day High $1.19
  • Year High $1.72

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

  • Last Earnings N/A
  • Ex-Dividend for 5/16 Dividend 12/09/2010
  • Dividend Payable 12/20/2010
  • Today N/A
  • Next Earnings (Estimated) 03/20/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $7.00
  • High Stock Price Target $8.00
  • Low Stock Price Target $6.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.08
  • Trailing P/E Ratio -1.34
  • Forward P/E Ratio -1.34
  • P/E Growth -1.34
  • Net Income $-37,340,000

Income Statement

Quarterly

Annual

Latest News of SLS

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

SELLAS Life Sciences Group, Inc. Frequently Asked Questions

  • What were the earnings of SLS in the last quarter?

    In the last quarter SELLAS Life Sciences Group, Inc. earnings were on Tuesday, August, 13th. The SELLAS Life Sciences Group, Inc. maker reported -$0.13 EPS for the quarter, beating analysts' consensus estimates of -$0.16 by $0.03.

  • What is the SELLAS Life Sciences Group, Inc. stock price today?

    Today's price of SELLAS Life Sciences Group, Inc. is $1.15 — it has increased by +4.11% in the past 24 hours. Watch SELLAS Life Sciences Group, Inc. stock price performance more closely on the chart.

  • Does SELLAS Life Sciences Group, Inc. release reports?

    Yes, you can track SELLAS Life Sciences Group, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the SELLAS Life Sciences Group, Inc. stock forecast?

    Watch the SELLAS Life Sciences Group, Inc. chart and read a more detailed SELLAS Life Sciences Group, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is SELLAS Life Sciences Group, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by SELLAS Life Sciences Group, Inc. stock ticker.

  • How to buy SELLAS Life Sciences Group, Inc. stocks?

    Like other stocks, SLS shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is SELLAS Life Sciences Group, Inc.'s EBITDA?

    SELLAS Life Sciences Group, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in SELLAS Life Sciences Group, Inc.’s financial statements.

  • What is the SELLAS Life Sciences Group, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in SELLAS Life Sciences Group, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including SELLAS Life Sciences Group, Inc.'s financials relevant news, and technical analysis. SELLAS Life Sciences Group, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for SELLAS Life Sciences Group, Inc. stock currently indicates a “sell” signal. For more insights, review SELLAS Life Sciences Group, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.